- Home
- BCV vs AGEN Comparison
BCV vs AGEN Comparison
Compare BCV & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCV
- AGEN
- Stock Information
- Founded
- BCV 1971
- AGEN 1994
- Country
- BCV United States
- AGEN United States
- Employees
- BCV N/A
- AGEN N/A
- Industry
- BCV Finance/Investors Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCV Finance
- AGEN Health Care
- Exchange
- BCV Nasdaq
- AGEN Nasdaq
- Market Cap
- BCV 130.9M
- AGEN 123.6M
- IPO Year
- BCV N/A
- AGEN 2000
- Fundamental
- Price
- BCV $23.70
- AGEN $3.85
- Analyst Decision
- BCV
- AGEN Buy
- Analyst Count
- BCV 0
- AGEN 2
- Target Price
- BCV N/A
- AGEN $14.50
- AVG Volume (30 Days)
- BCV 26.3K
- AGEN 470.9K
- Earning Date
- BCV 01-01-0001
- AGEN 11-11-2025
- Dividend Yield
- BCV 8.13%
- AGEN N/A
- EPS Growth
- BCV N/A
- AGEN N/A
- EPS
- BCV N/A
- AGEN N/A
- Revenue
- BCV N/A
- AGEN $101,706,000.00
- Revenue This Year
- BCV N/A
- AGEN $60.49
- Revenue Next Year
- BCV N/A
- AGEN N/A
- P/E Ratio
- BCV N/A
- AGEN N/A
- Revenue Growth
- BCV N/A
- AGEN N/A
- 52 Week Low
- BCV $14.09
- AGEN $1.38
- 52 Week High
- BCV $18.11
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- BCV 67.84
- AGEN 40.32
- Support Level
- BCV $22.66
- AGEN $3.96
- Resistance Level
- BCV $23.78
- AGEN $4.60
- Average True Range (ATR)
- BCV 0.37
- AGEN 0.25
- MACD
- BCV -0.04
- AGEN 0.01
- Stochastic Oscillator
- BCV 86.43
- AGEN 2.60
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).